Overall, the treatment of hypoparathyroidism in the ePatients and Épi-Hypo 2019 cohorts was qualitatively similar, except for magnesium supplements, native vitamin D, and teriparatide (PTH(1–34)). This evidence concerns the gene PTH and hypoparathyroidism.